Modjtahedi, H., Khelwatty, S.A., Kirk, R.S., Seddon, A.M., Essapen, S., Del Vecchio, C.A., Wong, A.J. and Eccles, S. (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer, 106, pp. 883-888. ISSN (print) 0007-0920Full text available as:
22223.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.
Download (672kB) | Preview
Background:The human epidermal growth factor receptor (EGFR) is an important therapeutic target in oncology, and three different types of EGFR inhibitors have been approved for the treatment of cancer patients. However, there has been no clear association between the expression levels of EGFR protein in the tumours determined by the FDA-approved EGFR PharmDx kit (Dako) or other standard anti-EGFR antibodies and the response to the EGFR inhibitors.Method:In this study, we investigated the potential of our anti-EGFR monoclonal antibodies (mAbs; ICR9, ICR10, ICR16) for immunohistochemical diagnosis of wild-type EGFR and/or the type-III deletion mutant form of EGFR (EGFRvIII) in formalin-fixed, paraffin-embedded human tumour specimens.Results:We found that the anti-EGFR mAb in the EGFR PharmDx kit stained both wild-type and EGFRvIII-expressing cells in formalin-fixed, paraffin-embedded sections. This pattern of EGFR immunostaining was also found with our anti-EGFR mAb ICR16. In contrast, mAbs ICR10 and ICR9 were specific for the wild-type EGFR.Conclusion:We conclude that mAbs ICR9 and ICR10 are ideal tools for investigating the expression patterns of wild-type EGFR protein in tumour specimens using immunohistochemistry, and to determine their prognostic significance, as well as predictive value for response to therapy with EGFR antibodies.British Journal of Cancer advance online publication, 7 February 2012; doi:10.1038/bjc.2012.27 www.bjcancer.com.
|Uncontrolled Keywords:||ICR10, EGFR, EGFRVIII, EGFR PharmDx, immunohistochemistry, epidermal-growth-factor, metastatic colorectal-cancer, receptor monoclonal-antibody, expression, cetuximab, therapy, panitumumab, carcinomas, ligands, target|
|Research Area:||Biological sciences|
|Faculty, School or Research Centre:||Faculty of Science, Engineering and Computing
Faculty of Science, Engineering and Computing > School of Life Sciences
|Depositing User:||Automatic Import Agent|
|Date Deposited:||10 Jul 2012 08:35|
|Last Modified:||07 Nov 2012 19:15|
Actions (Repository Editors)
|Item Control Page|